Prognostic parameter for high risk prostate cancer patients at initial presentation
Authors:
- 2 November 2017
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 78 (1) , 11-16
Abstract
Background: High‐risk prostate cancer can be defined by a patient's Gleason score (GS), prostate‐specific antigen (PSA) level, and clinical T (cT) stage, but a novel marker is needed due to heterogeneity of the disease. In this study, we evaluated whether intraductal carcinoma of the prostate (IDC‐P) confirmed by needle biopsy is an adverse prognostic parameter for progression‐free survival (PFS) and cancer‐specific survival (CSS) in patients with high‐risk prostate cancer.Methods: We retrospectively evaluated 204 patients with high‐risk prostate cancer treated by radical prostatectomy from 1991 to 2005 at Nagoya University and its affiliated hospitals. Data on each patient's PSA level, biopsy GS, cT stage, presence of Gleason pattern 5, presence of IDC‐P, percentage of the core involved with cancer, and maximum percentage of the core involved with cancer were analyzed.Results: The median follow‐up period was 108 months (range, 11‐257 months). Forty‐eight patients (24%) showed disease progression. Thirty‐four patients (17%) died of the disease during follow‐up. The IDC‐P component was detected in 74 (36%) needle biopsy samples. The 5‐, 10‐, and 15‐year CSS rates of the IDC‐P‐negative cases were 3.2%, 9.0%, and 23.7%; the corresponding rates of the IDC‐P‐positive cases were 23.9%, 33.7%, and 52.7%, respectively (P = 0.0001). In the Fine and Gray's model for PFS, IDC‐P, maximum percentage of the core involved with cancer, and cT stage were significantly associated (P = 0.013, P = 0.003, P = 0.007). In the Fine and Gray's model for CSS, only IDC‐P was significant (P = 0.027). In a multivariate Cox regression analysis, IDC‐P (P = 0.04; hazard ratio [HR], 1.95) and maximum percentage of the core involved with cancer (P = 0.021; HR, 0.43) were significant factors in predicting overall survival (OS).Conclusions: The presence of IDC‐P in a needle biopsy was a prognostic factor for PFS, CSS, and OS in patients with high‐risk prostate cancer who underwent radical prostatectomy. Multimodal pre‐and/or post‐ surgical therapy may be needed when IDC‐P is found in a needle biopsy specimen.Keywords
This publication has 27 references indexed in Scilit:
- Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk CategoriesEuropean Urology, 2017
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative IntentEuropean Urology, 2017
- Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Population‐Based StudyThe Prostate, 2017
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder TumoursEuropean Urology, 2016
- Patient-derived Xenografts Reveal that Intraductal Carcinoma of the Prostate Is a Prominent Pathology in BRCA2 Mutation Carriers with Prostate Cancer and Correlates with Poor PrognosisEuropean Urology, 2015
- Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer?The Prostate, 2014
- Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimensThe Prostate, 2014
- Morphologic Characterization of Preoperatively Treated Prostate Cancer: Toward a Post-Therapy Histologic ClassificationEuropean Urology, 2010
- Estimation of failure probabilities in the presence of competing risks: new representations of old estimatorsStatistics in Medicine, 1999
- Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate CancerJAMA, 1998